In a patient with a heterozygous prothrombin gene mutation who has COVID with minimal symptoms, do you recommend prophylactic and/or therapeutic anticoagulation?

Topics: Pediatric Oncology • Thrombosis • COVID-19 • Hematology • Pediatric Hematology • Benign Hematology • COVID-19 virus

Answer from: at Academic Institution

If the patient has no history of VTE, I would not recommend any anticoagulant treatment. Heterozygous prothrombin G20210A polymorphism is a relatively weak risk factor for VTE in comparison to antithrombin, protein C, or protein S deficiency, and in general, is not a finding that should guide decis...

Comments

Medical Oncologist at University of Washington School of Medicine
Great points by Dr. @Eliot C. Williams; we need mo...

Related Questions